Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Verinurad+Allopurinol with Cyclosporine or Rifampicin
NCT04532918Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of verinurad in chronic kidney disease (CKD), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Peak Concentration, Area Under Plasma Concentration-time Curve From Time Zero to Infinity and 1 more. Started Sep 2020; status: completed.
02
Drugs
verinurad
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04532918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532918.